ANANDA Scientific
Clinical-stage biopharmaceutical company focused on developing investigational therapeutics for neuropsychiatric disorders. The company develops proprietary liquid-based drug delivery formulations for active pharmaceutical ingredients and conducts IND-stage, double-blind, placebo-controlled clinical trials in collaboration with academic medical centers.
Industries
Nr. of Employees
medium (51-250)
Products
Investigational cannabidiol formulations using proprietary liquid delivery
Clinical-stage investigational drug candidates based on cannabidiol formulated with a liquid delivery platform intended to improve bioavailability and stability for neuropsychiatric indications.
Investigational cannabidiol formulations using proprietary liquid delivery
Clinical-stage investigational drug candidates based on cannabidiol formulated with a liquid delivery platform intended to improve bioavailability and stability for neuropsychiatric indications.
Services
Collaborative conduct of IND-stage clinical trials with academic institutions and clinical investigators.
Development and optimization of liquid delivery formulations to improve bioavailability, absorption consistency, and shelf stability.
Preparation and submission support for IND applications and regulatory engagement for clinical trial approvals.
Collaborative conduct of IND-stage clinical trials with academic institutions and clinical investigators.
Development and optimization of liquid delivery formulations to improve bioavailability, absorption consistency, and shelf stability.
Preparation and submission support for IND applications and regulatory engagement for clinical trial approvals.
Expertise Areas
- Clinical trial management
- Drug formulation and delivery
- Cannabinoid therapeutics (cannabidiol-based)
- Regulatory submissions (IND)
Key Technologies
- Liquid-based drug delivery systems
- Formulation development for oral APIs
- Cannabidiol (CBD) formulation
- Clinical trial design (double-blind, placebo-controlled)
News & Updates
Announcement of FDA approval of an IND application to evaluate a cannabidiol-based investigational drug for social anxiety disorder.
Announcement that the first patient was enrolled in a clinical trial evaluating an investigational cannabidiol formulation as an adjunctive treatment for opioid use disorder.
Collaboration with the University of Nebraska Medical Center and announcement of FDA approval for a PTSD clinical trial.
Announcement of a clinical trial in collaboration with the David Geffen School of Medicine at UCLA to evaluate a cannabidiol formulation for smoking cessation.
Announcement of a clinical trial evaluating a cannabidiol formulation for treatment of co-occurring opioid use disorder and chronic pain.
Signing of an MOU with an external partner to explore collaboration on accelerating development of treatments for PTSD.
Announcement of FDA approval of an IND application to evaluate a cannabidiol-based investigational drug for social anxiety disorder.
Announcement that the first patient was enrolled in a clinical trial evaluating an investigational cannabidiol formulation as an adjunctive treatment for opioid use disorder.
Collaboration with the University of Nebraska Medical Center and announcement of FDA approval for a PTSD clinical trial.
Announcement of a clinical trial in collaboration with the David Geffen School of Medicine at UCLA to evaluate a cannabidiol formulation for smoking cessation.
Announcement of a clinical trial evaluating a cannabidiol formulation for treatment of co-occurring opioid use disorder and chronic pain.
Signing of an MOU with an external partner to explore collaboration on accelerating development of treatments for PTSD.